Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12579679 | 0.88 | FFAR1 (0.58) | FFAR1RAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL12578008 | 0.88 | RAB9A (0.57) | FFAR1RAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL12578027 | 0.87 | FFAR1 (0.53) | FFAR1RAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL12577983 | 0.84 | RAB9A (0.53) | FFAR1RAB9ANPC1TDP1MAOB | |
| SCHEMBL12578014 | 0.84 | RAB9A (0.53) | FFAR1RAB9ANPC1TDP1MAOB | |
| SCHEMBL27892042 | 0.81 | RAB9A (0.60) | RAB9ANPC1TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1746848 | 0.81 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL12578044 | 0.81 | ALDH1A1 (0.46) | FFAR1RAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL2019514 | 0.80 | ALDH1A1 (0.56) | FFAR1RAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL1747394 | 0.80 | FFAR1 (0.82) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | FFAR1 64/4885RAB9A 4056/4885NPC1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.